...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Trillium

I agree he doesn't understand the concept of taking care of investors and more importantly the implications that has on future financings when a company is public. That is why I would much prefer to see Zenith stay private until it can be sold. (Hopefully soon!!)

Looking at RVX the failed trials have definitely hurt the share price but I think more detrimental has been the constant state of financial desperation coupled with lack of clarity and direction which in the markets eyes has completely overshadowed the scientific achievements and their commercial potential. To me Don is clearly not someone who should be running a public company.  

Share
New Message
Please login to post a reply